ArticleRSC pharmaceutics2026

Dual-adjuvant mucosal vaccine leveraging mast cell and TLR9 agonists for protection against poxvirus infection.

Connor T Murphy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.